{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Talazoparib in Advanced Breast Cancer With a Germline BRCA Mutation

Purpose of Activity

To provide information on the results of the EMBRACA Phase 3 study evaluating the use of talazoparib in advanced breast cancer patients with a germline BRCA mutation.

Learning Objectives/Outcomes

After completing this continuing education activity you will be able to:

  1. Summarize the purpose and design of the EMBRACA phase 3 evaluation of talazoparib in advanced breast cancer patients with a germline BRCA mutation.
  2. Outline the findings and implications of this study.
Price: $12.95

Credits:

  • ANCC 1.0 CH
  • DC - BON 1.0 CH
  • FL - BON 1.0 CH
  • GA - BON 1.0 CH

Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223.







Test Code: OT0219
Published: February 2019
Expires: 12/4/2020
Sources: Oncology Times
Passing Score: 7/10 (70%)
Authors: Richard Simoneaux
Topics: Cancer , Chemotherapy